Tags

Type your tag names separated by a space and hit enter

Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.
Expert Opin Drug Saf. 2015 Jun; 14(6):935-55.EO

Abstract

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 - 15% of patients. In clinical practice, statin intolerance limits effective treatment of patients at risk of, or with, cardiovascular disease. Knowledge of the most common adverse effects of statin therapy that might cause statin intolerance and the clear definition of this phenomenon is crucial to effectively treat patients with lipid disorders. Therefore, the aim of this position paper was to suggest a unified definition of statin intolerance, and to complement the recent EAS statement on SAMS, where the pathophysiology, diagnosis and the management were comprehensively presented.

Authors+Show Affiliations

Medical University of Lodz, Department of Hypertension, Chair of Nephrology and Hypertension , Zeromskiego 113; 90-549 Lodz , Poland +48 42 639 37 71 ; +48 42 639 37 71 ; maciejbanach@aol.co.uk.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25907232

Citation

Banach, Maciej, et al. "Statin Intolerance - an Attempt at a Unified Definition. Position Paper From an International Lipid Expert Panel." Expert Opinion On Drug Safety, vol. 14, no. 6, 2015, pp. 935-55.
Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf. 2015;14(6):935-55.
Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., Greenfield, R. S., Hovingh, G. K., Kostner, K., Serban, C., Lighezan, D., Fras, Z., Moriarty, P. M., Muntner, P., Goudev, A., ... Mikhailidis, D. P. (2015). Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opinion On Drug Safety, 14(6), 935-55. https://doi.org/10.1517/14740338.2015.1039980
Banach M, et al. Statin Intolerance - an Attempt at a Unified Definition. Position Paper From an International Lipid Expert Panel. Expert Opin Drug Saf. 2015;14(6):935-55. PubMed PMID: 25907232.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. AU - Banach,Maciej, AU - Rizzo,Manfredi, AU - Toth,Peter P, AU - Farnier,Michel, AU - Davidson,Michael H, AU - Al-Rasadi,Khalid, AU - Aronow,Wilbert S, AU - Athyros,Vasilis, AU - Djuric,Dragan M, AU - Ezhov,Marat V, AU - Greenfield,Robert S, AU - Hovingh,G Kees, AU - Kostner,Karam, AU - Serban,Corina, AU - Lighezan,Daniel, AU - Fras,Zlatko, AU - Moriarty,Patrick M, AU - Muntner,Paul, AU - Goudev,Assen, AU - Ceska,Richard, AU - Nicholls,Stephen J, AU - Broncel,Marlena, AU - Nikolic,Dragana, AU - Pella,Daniel, AU - Puri,Raman, AU - Rysz,Jacek, AU - Wong,Nathan D, AU - Bajnok,Laszlo, AU - Jones,Steven R, AU - Ray,Kausik K, AU - Mikhailidis,Dimitri P, Y1 - 2015/04/24/ PY - 2015/4/25/entrez PY - 2015/4/25/pubmed PY - 2016/1/13/medline KW - definition KW - muscle symptoms KW - risk factors KW - statin intolerance SP - 935 EP - 55 JF - Expert opinion on drug safety JO - Expert Opin Drug Saf VL - 14 IS - 6 N2 - Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 - 15% of patients. In clinical practice, statin intolerance limits effective treatment of patients at risk of, or with, cardiovascular disease. Knowledge of the most common adverse effects of statin therapy that might cause statin intolerance and the clear definition of this phenomenon is crucial to effectively treat patients with lipid disorders. Therefore, the aim of this position paper was to suggest a unified definition of statin intolerance, and to complement the recent EAS statement on SAMS, where the pathophysiology, diagnosis and the management were comprehensively presented. SN - 1744-764X UR - https://www.unboundmedicine.com/medline/citation/25907232/Statin_intolerance___an_attempt_at_a_unified_definition__Position_paper_from_an_International_Lipid_Expert_Panel_ L2 - http://www.tandfonline.com/doi/full/10.1517/14740338.2015.1039980 DB - PRIME DP - Unbound Medicine ER -